Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    Rebound Hyperbilirubinemia Risk Score

    Estimates risk of rebound hyperbilirubinemia after inpatient phototherapy.

    INSTRUCTIONS

    Use only in neonates ≥35 weeks gestational age (GA) treated with first episode inpatient phototherapy.

    When to Use
    Pearls/Pitfalls
    Why Use

    • Use in neonates ≥35 weeks GA requiring phototherapy to estimate the risk of rebound hyperbilirubinemia prior to discontinuing inpatient phototherapy.

    • Use only in infants with first episode inpatient phototherapy.

    • Rebound hyperbilirubinemia as defined by the index study is the return of total serum bilirubin (TSB) to or above the American Academy of Pediatrics (AAP) phototherapy threshold (guidelines) within 72 hours of phototherapy termination.

    • May be less applicable to older infants (≥6 days) and patients with significantly higher relative TSB values at termination of phototherapy.

    Clinicians and parents can make more informed decisions about whether the benefit of earlier phototherapy discontinuation outweighs the risk of rebound hyperbilirubinemia (Chang 2017).

    <38 weeks
    ≥38 weeks
    hours
    mg/dL

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Pearl W. Chang

    About the Creator

    Pearl W. Chang, MD, is a pediatrics specialist, currently practicing at Seattle Children’s Hospital in Washington. She graduated with honors from Stanford University School of Medicine in 2011. Dr. Chang’s primary research is focused on urinary tract infections and neonatal jaundice.

    Are you Dr. Pearl W. Chang? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    • Chionye Ossai, MD
    About the Creator
    Dr. Pearl W. Chang
    Are you Dr. Pearl W. Chang?
    Content Contributors
    • Chionye Ossai, MD